These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11687662)

  • 1. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector.
    Kim IH; Józkowicz A; Piedra PA; Oka K; Chan L
    Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13282-7. PubMed ID: 11687662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic correction of hypercholesterolemia in apoE-deficient mice by adenovirus-mediated in vivo gene transfer.
    Stevenson SC; Marshall-Neff J; Teng B; Lee CB; Roy S; McClelland A
    Arterioscler Thromb Vasc Biol; 1995 Apr; 15(4):479-84. PubMed ID: 7749859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice.
    Pastore L; Belalcazar LM; Oka K; Cela R; Lee B; Chan L; Beaudet AL
    Gene; 2004 Mar; 327(2):153-60. PubMed ID: 14980712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor.
    Oka K; Pastore L; Kim IH; Merched A; Nomura S; Lee HJ; Merched-Sauvage M; Arden-Riley C; Lee B; Finegold M; Beaudet A; Chan L
    Circulation; 2001 Mar; 103(9):1274-81. PubMed ID: 11238273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylated helper-dependent adenoviral vector expressing human Apo A-I for gene therapy in LDLR-deficient mice.
    Leggiero E; Astone D; Cerullo V; Lombardo B; Mazzaccara C; Labruna G; Sacchetti L; Salvatore F; Croyle M; Pastore L
    Gene Ther; 2013 Dec; 20(12):1124-30. PubMed ID: 23883962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia.
    Nomura S; Merched A; Nour E; Dieker C; Oka K; Chan L
    Gene Ther; 2004 Oct; 11(20):1540-8. PubMed ID: 15269711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia.
    Belalcazar LM; Merched A; Carr B; Oka K; Chen KH; Pastore L; Beaudet A; Chan L
    Circulation; 2003 Jun; 107(21):2726-32. PubMed ID: 12742997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector.
    Oka K; Belalcazar LM; Dieker C; Nour EA; Nuno-Gonzalez P; Paul A; Cormier S; Shin JK; Finegold M; Chan L
    Gene Ther; 2007 Feb; 14(3):191-202. PubMed ID: 16957769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors.
    Kashyap VS; Santamarina-Fojo S; Brown DR; Parrott CL; Applebaum-Bowden D; Meyn S; Talley G; Paigen B; Maeda N; Brewer HB
    J Clin Invest; 1995 Sep; 96(3):1612-20. PubMed ID: 7657831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
    Van Linthout S; Lusky M; Collen D; De Geest B
    Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer.
    De Geest B; Van Linthout S; Lox M; Collen D; Holvoet P
    Hum Gene Ther; 2000 Jan; 11(1):101-12. PubMed ID: 10646643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression.
    Cao H; Yang T; Li XF; Wu J; Duan C; Coates AL; Hu J
    Gene Ther; 2011 Feb; 18(2):173-81. PubMed ID: 20882053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved vascular gene transfer with a helper-dependent adenoviral vector.
    Wen S; Graf S; Massey PG; Dichek DA
    Circulation; 2004 Sep; 110(11):1484-91. PubMed ID: 15326058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses against tetracycline-dependent transactivators affect long-term expression of mouse erythropoietin delivered by a helper-dependent adenoviral vector.
    Lena AM; Giannetti P; Sporeno E; Ciliberto G; Savino R
    J Gene Med; 2005 Aug; 7(8):1086-96. PubMed ID: 15772935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary evaluation of a self-complementary AAV2/8 vector for hepatic gene transfer of human apoE3 to inhibit atherosclerotic lesion development in apoE-deficient mice.
    Osman E; Evans V; Graham IR; Athanasopoulos T; McIntosh J; Nathwani AC; Simons JP; Dickson G; Owen JS
    Atherosclerosis; 2009 May; 204(1):121-6. PubMed ID: 18930458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I.
    Van Linthout S; Collen D; De Geest B
    Hum Gene Ther; 2002 May; 13(7):829-40. PubMed ID: 11975849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration.
    Parks R; Evelegh C; Graham F
    Gene Ther; 1999 Sep; 6(9):1565-73. PubMed ID: 10490766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E.
    Harris JD; Schepelmann S; Athanasopoulos T; Graham IR; Stannard AK; Mohri Z; Hill V; Hassall DG; Owen JS; Dickson G
    Gene Ther; 2002 Jan; 9(1):21-9. PubMed ID: 11850719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity.
    Morral N; Parks RJ; Zhou H; Langston C; Schiedner G; Quinones J; Graham FL; Kochanek S; Beaudet AL
    Hum Gene Ther; 1998 Dec; 9(18):2709-16. PubMed ID: 9874269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors.
    Everett RS; Hodges BL; Ding EY; Xu F; Serra D; Amalfitano A
    Hum Gene Ther; 2003 Dec; 14(18):1715-26. PubMed ID: 14670123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.